BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock News

USA - NASDAQ:BBOT - US1079241022 - Common Stock

10.87 USD

+0.31 (+2.94%)

Last: 10/23/2025, 4:06:10 PM

11.36 USD

+0.49 (+4.51%)

After Hours: 10/23/2025, 4:06:10 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BBOT Latest News, Press Relases and Analysis

All

Press Releases

an hour ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

10 days ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

10 days ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming September Investor Healthcare Conferences

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming September Investor Healthcare Conferences

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition